Business

Know the Business

Centene is the country's largest government-payer-only managed care organization (MCO): roughly $175B of premiums per year flowing from state Medicaid agencies, CMS Marketplace subsidies, and Medicare D-SNP/PDP contracts to providers, with Centene keeping a thin 1–3 cent spread on every dollar. The economics are not insurance economics — they are spread economics on a regulated price book where rate adequacy lags actual medical cost trend by 6–18 months. 2025 is what happens when that lag becomes a chasm: a 360 bps Health Benefits Ratio (HBR) blowout simultaneously across Marketplace, Medicaid, and Medicare, capped by a $6.7B goodwill impairment that finally admitted the WellCare/Magellan acquisition era was overpaid for. The market is mostly fairly pricing the damage; what it likely under-appreciates is how mechanical the recovery is — and how regulatory, not economic, the next 24 months will be.

1. How This Business Actually Works

Centene is a pass-through, not a manufacturer. ~91 cents of every premium dollar leaves immediately as medical costs; ~7 cents covers SG&A; what remains is the entire profit pool.

Operating margin shown excluding the $7.3B impairment. The bar that moved is medical costs — a 360 bps swing on $175B of premiums is a $6B pre-tax hit, which is essentially the entire pre-impairment operating profit.

The four levers, in order of importance

The bid/rate-adequacy lever dominates. Medicaid rates are negotiated state-by-state on lagging actuarial data; Marketplace and Medicare bids are filed in the spring for the following plan year. Once the bid is in, the only defenses are utilization management (slow) and exiting the market for the following year (slower).

2. The Playing Field

Centene is a focused pure-play; the peers that consistently earn 10%+ ROE have all built earnings outside the insurance pool — UnitedHealth's Optum (PBM + provider + tech), Cigna's Evernorth, Elevance's Carelon. The pure-play government-payer MCOs (CNC, MOH, HUM) all just had their worst year of the past decade — same disease, same year.

The scatter is the punchline: Centene is the second-largest by revenue but sits at the bottom on margins, beneath even much smaller Molina. Scale does not solve the problem — UnitedHealth earns 8% op margins because half its operating profit comes from Optum, not insurance. Within the pure-MCO cohort, 2–5% is the structural ceiling, 0–2% the long-term average, and negative the periodic cost of getting bids wrong.

3. Is This Business Cyclical?

Not in the GDP sense. Centene's beta is 0.59, Medicaid demand is countercyclical, and provider unit prices are negotiated. The cycle is a regulatory underwriting cycle: premiums are set in advance based on assumed acuity, actual cost trend diverges, MCOs absorb the loss for 12–24 months, then reprice. Centene has been through three such cycles since the WellCare merger; the current one began Q2 2025.

Three separate forces hit at once in 2025:

The actionable point: this cycle is not driven by macro and will not be cured by macro. It is cured by a new bid book, which is mechanically locked in for the calendar year. That is why Marketplace pricing actions in Q3 2025 are the single most important forward indicator of 2026 earnings.

4. The Metrics That Actually Matter

Forget headline EPS in any year that includes a goodwill writedown or a premium deficiency reserve release. Five operating metrics explain 90% of the value creation in this business.

Operating cash flow includes timing effects of risk-corridor receivables and PDP premium float; the multi-year average is closer to 1.2x.

Why these and not the usual ratios

The conventional ratios — gross margin, asset turnover, even ROIC on a reported basis — are nearly meaningless for an MCO because the business has no cost of goods in the manufacturing sense and the asset base is dominated by pass-through investment portfolio. HBR is the entire game.

5. What I'd Tell a Young Analyst

Treat the consensus narrative with suspicion. The bull case ("scale leader, repricing for 2026, $2 of EPS in 2025 proves the model") and the bear case ("structural Medicaid pressure, OBBBA cuts coming, Marketplace subsidies expiring") are both partially right, which makes the stock a debate over magnitudes, not direction.

Watch four things, in order:

1. 2026 Q1 HBR by segment. Centene repriced 95% of the Marketplace book and bid below benchmark in 33 of 34 PDP regions. Either Q1 HBR drops 200+ bps in Marketplace and PDP, or the recovery thesis breaks.

2. Medicaid rate-to-acuity gap, state by state. Florida and New York are >10% of Medicaid premium each. A favorable rate update from either is materially valuable; an unfavorable one is the next leg down.

3. The OBBBA implementation calendar. Work-requirement and redetermination changes start meaningfully in 2027. Provider-tax and state-directed-payment changes start in 2028. The 2026 number is largely insulated; the 2027–2028 numbers are not.

4. Risk-adjustment receivable disclosure. This is the metric that broke 2025 and the one most easily missed. The 10-Q footnote on "premium and trade receivables" is the most useful page of the filing.

Avoid two common mistakes:

The first is anchoring on the goodwill impairment as new information. The $6.7B writedown is an admission that WellCare (2020, $17B) and Magellan (2022, $2.2B) were overpaid for, not a fresh signal about 2026 earnings power. The market priced this in months before the GAAP charge.

The second is treating Centene as a substitute for a hospital, pharmacy, or biotech name in a "healthcare basket." Its risk profile is regulatory and state-political, not clinical. The thesis lives or dies on legislative calendars and CMS rate notices, not on drug pipelines or admission volumes.